Clinical trial of Bailing capsules combined with ipratropium bromide in the treatment of patients with acute exacerabation of chronic obstructive pulmonary disease
10.13699/j.cnki.1001-6821.2024.03.003
- VernacularTitle:百令胶囊联合复方异丙托溴铵治疗慢性阻塞性肺疾病急性加重期患者的临床研究
- Author:
Chen SHI
1
;
Yu GAO
;
Hong-Yan LIU
;
Wen-Lan JI
;
Ping HU
Author Information
1. 陕西省结核病防治院、陕西省第五人民医院内四科,陕西西安 710100
- Keywords:
Bailing capsule;
compound ipratropium bromide solution inhalation;
acute exacerbation of chronic obstructive pulmonary disease;
clinical efficacy;
safety evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(3):317-320
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of Bailing capsules combined with compound ipratropium bromide solution inhalation in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods AECOPD patients were randomly divided into control group and treatment group.The control group was given compound ipratropium bromide 2.5 mL each time,3 times a day.On the basis of control group,the treatment group was given Bailing capsules 2.5 g,3 times a day,orally.Two groups were treated for 2 weeks.The clinical efficacy,forced vital capacity(FVC),arterial partial pressure of oxygen(PO2),serum levels of tumor necrosis factor-α(TNF-α),soluble intercellular adhesion molecule-1(sIC AM-1),soluble triggering receptor expressed on myeloid cells-1(sTREM-1)and adverse drug reactions were compared between two groups.Results Forty-nine patients were enrolled in both the treatment group and the control group,and no patients dropped out.After treatment,the total effective rates of treatment and control groups were 95.92％(47 cases/49 cases)and 83.67％(41 cases/49 cases)with significant difference(P＜0.05).After treatment,FVC of the treatment and control groups were(2.89±0.41)and(2.66±0.35)L;PO2 were(83.39±8.02)and(76.78±7.55)mmHg;arterial partial carbon dioxide pressure were(48.47±5.11)and(56.02±6.42)mmHg;the levels of TNF-α were(41.14±6.03)and(69.64±8.29)ng·L-1;the levels of sICAM-1 were(327.52±31.19)and(420.20±38.88)μg·L-1;the levels of sTREM-1 were(31.14±3.22)and(38.85±5.29)ng·L-1;the differences were statistically significant(all P＜0.05).The adverse drug reactions in treatment group were nausea and upper abdominal discomfort,which in control group were upper abdominal discomfort.The total incidences of adverse drug reactions in the treatment and control groups were 4.08％and 2.04％,without significant difference(P＞0.05).Conclusion The clinical efficacy of Bailing Capsules combined with compound ipratropium bromide solution inhalation in the treatment of AECOPD patients is better than that of compound ipratropium bromide alone,without increasing the incidence of adverse drug reactions.
